Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
12/9/20, 2:00 PM
America/Chicago UTC -5
The spectrum of treatment modalities for cancer immunotherapy has expanded greatly, and now includes the use of antibodies, immune stimulation, cancer vaccines, adoptive T cell transfer, immune checkpoint inhibitors, and oncolytic virus therapies.
Join experts from Nimbus Therapeutics, Phillip Morris International and WuXi AppTec to review multiple immunology assays that enable the exploration of the function of a variety of immune cells including T cells, B cells, NK cells, and macrophages. Through case studies, we will discuss the importance of interrogating the stimulation, differentiation, and suppression of immune cells, and also the interaction between immune system components and cancer cells.
Lastly, we will review the WuXi AppTec immunology platform and its application for the evaluation of drug efficacy in preclinical research.
-Cancer Immunotherapy Background and Development
-Mechanism of the Immune System in Tumorigenesis
-Utilizing the WuXi AppTec In Vitro Immunology Platform to advance immuno-oncology drug discovery
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Cancer Immunotherapy Background and Development, Mechanism of the Immune System in Tumorigenesis, Utilizing the WuXi AppTec In Vitro Immunology Platform to advance immuno-oncology drug discovery
Christine Loh, Diego Marescotti, Tienan Wang